Taken together, our studies demonstrate that SIX4 controls STING expression and activation in colon cancer cells, providing an additional mechanism and a potential clinical genetic marker to predict effective response of patients with colon cancer to immune checkpoint blockade therapies. This evidence concerns the gene SIX4 and malignant colon neoplasm.